Mode
Text Size
Log in / Sign up

Low-grade serous ovarian cancer

Part of Cancer

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer
Allergy & Immunology Sys. Review
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer New immune targets offer hope for ovarian cancer patients
This narrative review synthesizes evidence on follicular T cell subsets, tertiary lymphoid structures, and other immune features in ovarian …
A review highlights new immune system features that could help doctors predict treatment success and find better ways to fight ovarian cance…
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
Infectious Disease Sys. Review
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Case report review of fertility-sparing surgery for ovarian borderline mucinous tumor with carcinosarcomatous mural nodule
Rheumatology Sys. Review
Case report review of fertility-sparing surgery for ovarian borderline mucinous tumor with carcinosarcomatous mural nodule A rare ovarian tumor diagnosis explained in a single patient case
This source is a case report review describing a 27-year-old female patient with an ovarian borderline mucinous tumor and carcinosarcomatous…
Doctors treated a 27-year-old woman with a rare ovarian tumor using fertility-sparing surgery and chemotherapy, with no signs of the cancer …
Nomogram predicts survival in uterine serous carcinoma using SEER and hospital data
Oncology Cohort
Nomogram predicts survival in uterine serous carcinoma using SEER and hospital data New Tool Helps Doctors Predict Uterine Cancer Survival
This retrospective cohort study of 8,204 patients with uterine serous carcinoma developed a nomogram for overall survival prediction.
A new computer model helps doctors give honest survival estimates for patients with a deadly form of uterine cancer.
Ovarian cancer diagnoses decreased during COVID-19 pandemic years at a Swiss center
Oncology Cohort
Ovarian cancer diagnoses decreased during COVID-19 pandemic years at a Swiss center Lockdowns Didn't Hurt Ovarian Cancer Survival
This retrospective cohort study of 218 patients at Bern University Hospital found primary ovarian cancer diagnoses decreased in 2020 and 202…
When the world shut down in 2020, hospitals faced a scary reality.
Conference report on AI ensemble for histopathological classification of ovarian carcinoma subtypes
Oncology
Conference report on AI ensemble for histopathological classification of ovarian carcinoma subtypes AI Can Now Tell Apart Two Ovarian Cancers That Look Nearly Identical
This conference report describes a preclinical computational study using an attention-guided CNN ensemble to classify high-grade versus low-…
This technology could prevent misdiagnosis and ensure patients get the most effective treatment for their specific cancer type from day one.
Separate molecular profiling of mixed endometrial carcinoma components yields limited prognostic data in a small retrospective cohort
Oncology Cohort
Separate molecular profiling of mixed endometrial carcinoma components yields limited prognostic data in a small retrospective cohort Separate tumor profiling may reveal hidden risks in mixed endometrial cancer
This hypothesis-generating retrospective cohort analysis included 8 patients with mixed endometrial carcinomas (MEEC).
In mixed endometrial cancer, testing each tumor component separately could uncover risk profiles that standard testing misses.
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer
Oncology RCT
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer New Drug Combo Extends Survival for Tough Ovarian Cancer Cases
In a phase 3 randomised controlled trial of 381 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel significan…
This combination offers a new, simpler option for patients who have run out of standard treatments.
STAT1 and IL-7 show diagnostic potential for ovarian carcinoma subtypes in cohort study
Allergy & Immunology Cohort
STAT1 and IL-7 show diagnostic potential for ovarian carcinoma subtypes in cohort study Two Tiny Signals Could Help Doctors Tell Apart Two Ovarian Cancers
A cohort study analyzed transcriptome data from 68 patients with high-grade and low-grade serous ovarian carcinoma.
Two tiny gene signals may help doctors distinguish between two ovarian cancer types when biopsy results are unclear, guiding the right treat…
Retrospective cohort study of 217 surgically treated borderline ovarian tumors in Southern Sweden compares conservative versus complete staging surgery
Oncology Cohort
Retrospective cohort study of 217 surgically treated borderline ovarian tumors in Southern Sweden compares conservative versus complete staging surgery A Gentler Surgery for Ovarian Tumors May Be Safer Than We Thought
This retrospective, population-based cohort review evaluated 217 patients with borderline ovarian tumors (BOT) in Southern Sweden.
A less invasive surgery for borderline ovarian tumors may be just as safe as the standard approach, offering fewer complications without har…
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier
Oncology Sys. Review
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …
Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study finds
Allergy & Immunology Cohort
Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study finds Chemotherapy linked to immune system changes in ovarian cancer patients
An observational cohort study of 107 HGSOC patients and 50 healthy controls found chemotherapy was associated with modulation of NK cell rec…
Chemotherapy in ovarian cancer may restore natural killer cell markers to healthy levels and boost proteins that help immune cells fight tum…